---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-023162"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:47:51.333391+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma annual meeting: all director nominees elected, auditor ratified, say-on-pay passes

## Summary
- Eight director nominees elected with 258k-281k votes for each; broker non-votes of 1.63M.
- Ratification of EisnerAmper as auditor passed: 1,806,011 for, 126,343 against, 15,139 abstain.
- Advisory vote on named executive officer compensation passed: 244,160 for, 60,487 against, 9,370 abstain.

## SEC filing metadata
- accession: 0000950170-23-023162
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023023162/0000950170-23-023162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023023162/crbp-20230518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-023162
- JSON: https://secwatch.observer/filing/0000950170-23-023162.json
- Plain text: https://secwatch.observer/filing/0000950170-23-023162.txt

## Key facts
- Shareholder Votes
  Corbus Pharmaceuticals Holdings, Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2023 at the 2023-05-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2023 was approved based upon the following votes: Votes For Votes Against Abstentions 1,806,011 126,343 15,139
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023023162/0000950170-23-023162-index.htm
- Shareholder Votes
  Corbus Pharmaceuticals Holdings, Inc. shareholders approved Election of directors at the 2023-05-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The election of each of Yuval Cohen, Alan Holmer, Avery W. Catlin, Peter Salzmann, John Jenkins, Rachelle Jacques, Anne Altmeyer, and Yong Ben as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term. The votes were cast for this matter as follows: Nominees Votes For Votes Withheld Broker Non-Votes Yuval Cohen 273,627 40,390 1,633,476 Alan Holmer 277,778 36,239 1,633,476 Avery W. Catlin 279,436 34,581 1,633,476 Rachelle Jacques 258,401 55,616 1,633,476 John Jenkins 280,600 33,417 1,633,476 Peter Salzmann 278,204 35,813 1,633,476 Anne Altmeyer 280,813 33,204 1,633,476 Yong Ben 281,040 32,977 1,633,476
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023023162/0000950170-23-023162-index.htm
- Shareholder Votes
  Corbus Pharmaceuticals Holdings, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2023-05-18 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statement: Votes For Votes Against Abstentions Broker Non-Votes 244,160 60,487 9,370 1,633,476
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023023162/0000950170-23-023162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.